Sturm, Ruger & Co. Reports Full-Year Net Loss, Implements Poison Pill Amidst Activist Pressure
Summary
Sturm, Ruger & Co. reported a full-year net loss for 2025 and adopted a poison pill in response to activist investor Beretta Holding S.A., alongside significant board changes.
Key Events
-
Full-Year 2025 Net Loss Reported
The company reported a net loss of $4.4 million for the fiscal year ended December 31, 2025, a significant decline from a net income of $30.6 million in 2024. Basic EPS fell to $(0.27) from $1.79.
-
Gross Profit and Operating Income Decline
Gross profit decreased to $81.2 million (14.9% margin) in 2025 from $114.4 million (21.4% margin) in 2024. Operating income shifted to a loss of $12.3 million in 2025 from an income of $31.7 million in 2024.
-
Stockholder Rights Plan Adopted
A limited-duration stockholder rights plan (poison pill) was adopted on October 14, 2025, expiring October 13, 2026. This plan, triggered by 10% beneficial ownership, was a direct response to activist investor Beretta Holding S.A.'s significant stake, aiming to protect shareholder value and provide the Board time to evaluate options.
-
Board of Directors Changes
On February 22, 2026, three long-serving directors retired, and three new directors (Aaron Rivers, Stephen Timm, and Lorin Cassidy Wolfe) were immediately appointed to fill the vacancies. This follows an 8-K filing on 2026-02-23.
Analysis
Sturm, Ruger & Co. reported a significant decline in financial performance for fiscal year 2025, moving from a net income of $30.6 million in 2024 to a net loss of $4.4 million. This downturn was driven by a sharp decrease in gross profit and operating income, despite a slight increase in net sales. Concurrently, the company adopted a limited-duration stockholder rights plan (poison pill) on October 14, 2025, in response to activist investor Beretta Holding S.A. accumulating a significant stake. This defensive measure, which triggers at 10% beneficial ownership, aims to prevent a change of control without fair compensation to all shareholders. The company also announced the retirement of three directors and the appointment of three new ones, further signaling a period of significant corporate governance shifts amidst external pressure. While the company completed a strategic acquisition of Anderson Manufacturing assets and maintained compliance with debt covenants, the overall picture reflects a challenging financial year coupled with proactive measures to defend against activist investors.
At the time of this filing, RGR was trading at $37.95 on NYSE in the Manufacturing sector, with a market capitalization of approximately $605.1M. The 52-week trading range was $28.33 to $48.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.